GlassScriptPhysician profile
Natalie C Gilley
NPI 1093953911
$3,292.74
in general payments reported to CMS, 2019-2025
32 companies · $628 in 2025
The $628 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $738 · 2023: $777 · 2024: $782 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.53 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $725.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $325.04 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.78 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $225.94 | 2021-2025 | Otezla, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $156.47 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $156.29 | 2023 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $154.34 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $145.30 | 2021-2025 | |
| Lilly USA, LLC | $133.58 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Nestle Healthcare Nutrition INC. | $120.48 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $102.56 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $101.17 | 2021-2024 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $89.85 | 2024-2025 | Farxiga, Airsupra |
| Corcept Therapeutics | $84.80 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $60.56 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.45 | 2022 | |
| Merck Sharp & Dohme LLC | $51.56 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.01 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $45.13 | 2024 | Gemtesa |
| Seqirus USA INC | $38.50 | 2021-2022 | |
| Cipher Pharmaceuticals US LLC | $33.03 | 2025 | Natroba, Spinosad |
| Phathom Pharmaceuticals, INC. | $31.23 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $30.39 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $24.57 | 2022 | |
| Boston Scientific Corporation | $19.94 | 2025 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.91 | 2024 | Xifaxan, Trulance |
| Tempus Ai, INC | $16.25 | 2024 | |
| Amarin Pharma, INC. | $15.74 | 2021 | |
| Almatica Pharma LLC | $15.51 | 2021 | |
| Insulet Corporation | $15.47 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.58 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Gilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.